• Memorify

  Participated · Seed · Mar 2026

  Memorify offers a digital platform designed to take users’ personal photos and automatically curate them into coherent, chronological life stories. By turning disorganized image libraries into narrative timelines, the product aims to help consumers preserve and relive their memories more meaningfully. The service targets individuals who struggle with managing large collections of photos spread across devices and cloud services. Memorify positions itself as a consumer-focused solution, emphasizing ease of use and automated organization. The company is headquartered in Cambridge, United Kingdom. Recently, it secured new capital to accelerate product development and early market entry, but it has not yet disclosed user numbers, revenue figures, or other key operating metrics. The fresh funding places the business in a stronger financial position to refine its technology and expand its customer base.

• Ablatus Therapeutics

  Led · Equity · Jul 2016

  Ablatus Therapeutics is developing Bimodal Electric Tissue Ablation (BETA), an innovative improvement over existing tissue ablation techniques. The company aims to offer greater clinical options and to improve patient outcomes. On 30 June 2021 it received an £85,000 investment from Turquoise for the Low Carbon Innovation Fund 2. That contribution is part of an overall funding round the article states could reach £1.5 million. Turquoise is described in the article as a UK merchant bank specialising in energy, environment and efficiency. The article does not disclose further financial terms, instruments or operating metrics. Ablatus Therapeutics is commercialising a bimodal electric tissue ablation (BETA) technology that advances conventional radiofrequency ablation (RFA) by adding DC current to the needle alongside AC. BETA attracts moisture and reduces charring and dehydration, which the article says contributed to recurrence rates of almost 50% with previous methods. The company reports BETA improves ablation zone size and has the potential to treat tumours previously considered untreatable. The technique was developed at the Norfolk and Norwich Hospital, which retains a significant equity stake in the business and whose spinout this is. Ablatus intends to use the recently raised capital to support development of its product for treating cancer patients. In May the company closed a £500,000 investment round to advance its clinical and commercial development efforts.

No current team members are available.